KROSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Keros Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$11.06+0.40 (+3.75%)
Close on Oct 19, 2026
- Market cap
- $218.99M
- P/E (TTM)
- –
- Dividend yield
- –
Dividends
Keros Therapeutics has not reported a dividend
No dividend per share appears in Keros Therapeutics's annual filings since fiscal 2018.